Abstract
Intracerebral hemorrhage (ICH) imparts a higher mortality and morbidity than ischemic stroke. The therapeutic interventions that are currently available focus mainly on supportive care and secondary prevention. There is a paucity of evidence to support any one acute intervention that improves functional outcome. This chapter highlights current treatment targets for ICH based on the pathophysiology of the disease.
MeSH terms
-
Anti-Inflammatory Agents / therapeutic use
-
Blood Pressure / physiology
-
Brain Edema / drug therapy
-
Brain Edema / etiology
-
Celecoxib
-
Cerebral Amyloid Angiopathy / complications
-
Cerebral Amyloid Angiopathy / drug therapy
-
Cerebral Hemorrhage / etiology
-
Cerebral Hemorrhage / genetics
-
Cerebral Hemorrhage / therapy*
-
Clinical Trials as Topic
-
Collagen Type IV / genetics
-
Cyclooxygenase 2 Inhibitors / therapeutic use
-
Factor VIIa / therapeutic use
-
Hematoma / drug therapy
-
Hematoma / etiology
-
Humans
-
Pyrazoles / therapeutic use
-
Recombinant Proteins / therapeutic use
-
Sulfonamides / therapeutic use
Substances
-
Anti-Inflammatory Agents
-
COL4A1 protein, human
-
Collagen Type IV
-
Cyclooxygenase 2 Inhibitors
-
Pyrazoles
-
Recombinant Proteins
-
Sulfonamides
-
recombinant FVIIa
-
Factor VIIa
-
Celecoxib